Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 7Colorectal Neoplasms 7Carcinoma, Non-Small-Cell Lung 2Rectal Neoplasms 1Neurofibromatosis 1 1Neoplasm Metastasis 1Hereditary Sensory and Autonomic Neuropathies 1Gastrointestinal Neoplasms 1Colonic Neoplasms 1

Interventions

Fluorouracil 38Capecitabine 31Oxaliplatin 30Leucovorin 30Radiotherapy 21Irinotecan 20Bevacizumab 15Radiation 12Cetuximab 12pembrolizumab 9Gemcitabine 7trifluridine tipiracil drug combination 5dehydroftorafur 5cediranib 5Radiotherapy, Intensity-Modulated 5Folfox protocol 5Erlotinib Hydrochloride 5Cisplatin 5Carboplatin 5trametinib 4Surgical Procedures, Operative 4Paclitaxel 4Neoadjuvant Therapy 4Gene Expression Profiling 4Cyclophosphamide 4sargramostim 3binimetinib 3Trifluridine 3Sorafenib 3Pemetrexed 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Rectal Neoplasms × encorafenib × Clear all
NCT04044430 2023-01-09

Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer

University of California, San Francisco

Phase 1 Terminated
2 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡